14.10.2013 14:30:00
|
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amarin Corporation plc
NEW YORK, Oct. 14, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Amarin Corporation plc ("Amarin" or the "Company") (NasdaqGM: AMRN). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
The investigation concerns whether Amarin and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On October 11, 2013, shares of Amarin fell $1.28 or 20.09% to close at $5.09 after the FDA released its briefing documents for the October 16, 2013 advisory committee review of Amarin's application seeking expanded approval for the use of its fish oil-based drug, Vascepa, in the treatment of adult patients with high triglycerides with mixed dyslipidemia. The FDA briefing documents raised questions about the mineral oil placebo potentially negatively impacting the control group data and consequentially overstating Vascepa's effectiveness.
If you are aware of any facts relating to this investigation, or purchased shares of Amarin, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
SOURCE Bronstein, Gewirtz & Grossman, LLC
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Amarin Corporation PLC (spons. ADRs)mehr Nachrichten
29.10.24 |
Ausblick: Amarin mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
15.10.24 |
Erste Schätzungen: Amarin legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) | |
30.07.24 |
Ausblick: Amarin stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) |
Analysen zu Amarin Corporation PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Amarin Corporation PLC (spons. ADRs) | 0,52 | 5,26% |